Jose R. Arribas

Jose R. Arribas publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jose R. Arribas sits on this spectrum.

Jose R. Arribas D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jose R. Arribas sits on this spectrum.

Best Publications

• Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

  Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  4700
  Citations

• Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

  Joel E. Gallant;Edwin Dejesus;José R. Arribas;Anton L. Pozniak

  1220
  Citations

• Lopinavir–Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection

  Sharon Walmsley;Barry Bernstein;Martin King;José Arribas

  863
  Citations

• Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study

  Hans-Jürgen Stellbrink;Chloe Orkin;Jose Ramon Arribas;Juliet Compston

  473
  Citations

• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

  Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  416
  Citations

• Clinical Management of Ebola Virus Disease in the United States and Europe.

  Timothy M. Uyeki;Aneesh K. Mehta;Richard T. Davey;Allison M. Liddell

  411
  Citations

• Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

  Jan van Lunzen;Franco Maggiolo;José R Arribas;Aza Rakhmanova

  395
  Citations

• Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

  Anthony Mills;Jose R. Arribas;Jaime Andrade-Villanueva;Giovanni DiPerri

  375
  Citations

• Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.

  Alberto M Borobia;Antonio J Carcas;Mayte Pérez-Olmeda;Luis Castaño

  369
  Citations

• Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.

  Julia Del Amo;Rosa Polo;Santiago Moreno;Asunción Díaz

  356
  Citations

• Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.

  Jose R. Arribas;Anton L. Pozniak;Joel E. Gallant;Edwin DeJesus

  338
  Citations

• Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

  Anton L. Pozniak;Joel E. Gallant;Joel E. Gallant;Edwin DeJesus;Jose R. Arribas;Jose R. Arribas

  317
  Citations

• Smoking-Related Health Risks Among Persons With HIV in the Strategies for Management of Antiretroviral Therapy Clinical Trial

  Alan R. Lifson;Jacqueline Neuhaus;Jose Ramon Arribas;Mary van den Berg-Wolf

  314
  Citations

• A cohort of patients with COVID-19 in a major teaching hospital in Europe

  Alberto M Borobia;Antonio J Carcas;Francisco Arnalich;Rodolfo Álvarez-Sala

  281
  Citations

• Pegylated Ifn-α2b plus ribavirin as therapy for chronic hepatitis C in Hiv-infected patients

  Mayte Pérez-Olmeda;Marina Núñez;Miriam Romero;Juan González

  281
  Citations

• Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

  Anton Pozniak;Jose R. Arribas;Joseph Gathe;Samir K. Gupta

  258
  Citations

• Severe Nucleoside-Associated Lactic Acidosis in Human Immunodeficiency Virus–Infected Patients: Report of 12 Cases and Review of the Literature

  Vicente Falcó;Dolors Rodríguez;Esteban Ribera;Esteban Martínez

  255
  Citations

• Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

  Nicholas I. Paton;Cissy Kityo;Anne Hoppe;Andrew Reid

  236
  Citations

• Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications.

  Juan R Rey;Juan Caro‐Codón;Sandra O. Rosillo;Ángel M. Iniesta

  236
  Citations

• Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

  Joseph J. Eron;Jürgen K. Rockstroh;Jacques Reynes;Jaime Andrade-Villanueva

  228
  Citations